Welcome to our dedicated page for Can-Fite BioPharma Ltd. news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. stock.
Can-Fite BioPharma Ltd. (CANF) is a clinical-stage biopharmaceutical innovator advancing oral therapies for cancer, liver diseases, and inflammatory conditions through its proprietary A3 adenosine receptor (A3AR) platform. This page serves as your definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and industry professionals will find curated press releases detailing progress across Can-Fite’s pipeline, including Phase II/III trials for Piclidenoson in psoriasis and Namodenoson’s dual applications in liver cancer and NASH. All content is verified through primary sources to ensure accuracy and timeliness.
Key updates cover regulatory milestones, partnership announcements, and peer-reviewed research findings. The collection emphasizes developments in targeted small molecule therapeutics while maintaining accessibility for both specialist and general audiences.
Bookmark this page to efficiently monitor Can-Fite’s advancements in addressing multi-billion dollar medical markets through its differentiated A3AR approach. Check regularly for critical updates that may influence market positioning and therapeutic innovation.
Can-Fite BioPharma announced that its veterinary partner, Vetbiolix, has initiated a safety and efficacy study of Piclidenoson for treating canine osteoarthritis, targeting a market expected to reach
Can-Fite BioPharma (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the H.C. Wainwright 7th Annual Israel Conference on November 15, 2021, at 12:30 PM ET. The presentation will emphasize Can-Fite's advanced-stage pipeline, including a Phase III study in psoriasis with results expected in Q1 2022. Upcoming studies include a Phase II study in NASH and a pivotal Phase III trial in liver cancer. Can-Fite is focused on developing proprietary drugs for inflammatory diseases, cancer, and liver conditions, including the candidates Piclidenoson and Namodenoson.
Can-Fite BioPharma (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present research on the CBD Rich T3/C15 cannabis fraction at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting from November 12-15, 2021. The study indicates that this cannabis fraction inhibits the growth of HEP-3b hepatocellular carcinoma cells via the A3 Adenosine Receptor. This inhibitory activity suggests potential therapeutic applications in liver cancer treatment.
Can-Fite BioPharma (NYSE: CANF) announced the granting of a patent for its NASH drug candidate, Namodenoson, in Hong Kong and Mexico, with a notice of allowance in Japan. This patent enhances Can-Fite's intellectual property in treating ectopic fat accumulation related to NAFLD and NASH, projected to reach a $35 billion market by 2025. Namodenoson has successfully completed a Phase IIa study and is currently in Phase IIb trials. The company has secured about $20 million in non-dilutive payments for Namodenoson across multiple regions.
Can-Fite BioPharma (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the 5th Annual Antifibrotic Drug Development Summit on November 3, 2021. Her presentation will highlight innovative strategies for promoting tissue regeneration, focusing on clinical trial data for Namodenoson, which showed a dose-dependent reduction in liver fat and fibrosis in a Phase IIa study. The Phase IIb study is currently approved and underway, while Can-Fite continues to advance its clinical pipeline in cancer and liver diseases.
Can-Fite BioPharma Ltd (NYSE: CANF) announced the publication of a study on Namodenoson for treating non-alcoholic fatty liver disease (NASH) in the journal Alimentary Pharmacology & Therapeutics. The Phase IIa trial met its endpoints, showcasing significant anti-steatotic, anti-fibrotic, and anti-inflammatory effects. A Phase IIb trial is set to enroll patients in Q4 2021. The market for NASH treatments is projected to reach $35-40 billion by 2025. With no current U.S. approved drugs for NASH, the potential for Namodenoson is substantial.
Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the NASH Investor Conference on
Can-Fite BioPharma Ltd. (NYSE American: CANF) will have CEO Dr. Pnina Fishman present at the Benzinga Healthcare Small Cap Conference on September 29, 2021.
The presentation will include a panel discussion on medical cannabis and insights into Can-Fite’s drug development efforts, including ongoing trials for Piclidenoson and Namodenoson targeting psoriasis and liver cancer. With FDA designations for Namodenoson, Can-Fite aims to capture significant market opportunities in the pharmaceutical industry.
Can-Fite BioPharma Ltd (NYSE American: CANF) has secured approximately
Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will focus on the company's proprietary small molecule drugs aimed at inflammatory, cancer, and liver diseases, with a special emphasis on Piclidenoson and Namodenoson, which are advancing through various clinical trials. The presentation will be available on the conference portal at 7:00 AM ET on September 13.
FAQ
What is the current stock price of Can-Fite BioPharma Ltd. (CANF)?
What is the market cap of Can-Fite BioPharma Ltd. (CANF)?
